June 22, 2024
Urea Cycle Disorder Treatment Market

Urea Cycle Disorder Treatment is Expected to be Flourished by Growing Awareness and Screening Programs

Urea cycle disorders (UCD) are a group of rare, inherited, metabolic disorders that affect the body’s ability to remove ammonia from the bloodstream. UCD affects around 1 in 35,000 newborns globally. The urea cycle is a series of biochemical reactions that produces urea, which the body passes out of the body in urine. UCD occurs due to the deficiency of any of the enzymes or transporters involved in the urea cycle. Common symptoms of UCD are vomiting, lack of appetite, seizures, intellectual disability, behavioral problems, unusual tiredness or poor muscle tone. Early diagnosis and lifelong treatment with specialized diets, nutrient supplements, medications, and sometimes gene or stem cell therapies can help improve health outcomes.

The global urea cycle disorder treatment market is estimated to be valued at US$ 1518.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

Growing awareness and screening programs: Due to growing advocacy by patient communities and awareness campaigns by non-profit organizations and government bodies, there is increased awareness among general public and healthcare providers about urea cycle disorders. Some countries have also mandated screening of newborns for certain UCDs. This has led to early diagnosis and better management of the disorders. Screening programs are helping in diagnosing more number of UCD patients, thereby driving the market growth.

Specialized treatment options: Advancements in research have led to development of specialized diet plans, medications, and supportive therapies specifically for different forms of UCDs. Different treatment options help address symptoms as well as long term health issues effectively. Availability of personalized treatment protocol is boosting the demand of UCD management.

Segment Analysis

Urea cycle disorders treatment market is segmented in two broad categories:

The disorders segment is further segmented into five types which dominates the market. These include ornithine transcarbamylase (OTC) deficiency, citrullinemia, argininosuccinic aciduria (ASA), hyperammonemia and other genetic mutations affecting the urea cycle. Among these, OTC deficiency accounts for around 30-35% of UCD cases and is the most common urea cycle disorder. It occurs in 1 in 14,000 live births and only affects males.

The therapeutics segment is led by nitrogen scavengers which remove excess ammonia from the blood through alternative excretion pathways. Drugs like sodium phenylbutyrate and glycerol phenylbutyrate together hold over 65% market share as first line treatments.

Pest Analysis

Political: Government initiatives promote research into rare diseases like UCD. The Rare Disease Act in the US provides incentives for drug development.

Economic: Rising healthcare spending boosts the market. However, high treatment costs can be a challenge.

Social: Growing patient support groups raise disease awareness and demand for improved care options.

Technological: Advances in genetic testing facilitate early diagnosis. Research into gene and stem cell therapies holds promise for future treatments.

Key Takeaways

The Global Urea Cycle Disorder Treatment Market Growth is expected to witness strong over the forecast period. The global urea cycle disorder treatment market is estimated to be valued at US$ 1518.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031.

Regional analysis:

North America is the largest regional market driven by the established healthcare system and supportive patient support initiatives in the US and Canada. The European market is growing steadily while Asia Pacific region will expand at the fastest pace led by China and India.

Key players:

Key players operating in the urea cycle disorder treatment market are Charles River, Roche, Illumina, and Agilent Technologies, Inc. Sodium phenylbutyrate and glycerol phenylbutyrate from Horizon Therapeutics dominate the nitrogen scavenging drug segment. Other prominent players are developing new drug formulations and combinations to improve outcomes.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it